Biomedical subjects

M F Lubin

Publications and source records attributed to M F Lubin.

5 recordsLinked to original sources

PubMed1996

Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia.

Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma. The design was a case-control study. The patient population was from a large municipal teaching hospital in Atlanta, Georgia. In logistic regression models, the risk of colorectal adenoma or adenocarcinoma decreased in the first two years of continuous NSAID use in a linear, time-dependent manner. The risk of colorectal neoplasia after two years of continuous NSAID use was reduced significantly (P < 0.01) as compared to nonusers. Risk reduction appeared greater for adenocarcinoma than adenoma. The use of SAIDs, calcium, multivitamins, and psyllium, as prescribed to our patient population during the mean six-year study period, conferred no measurable risk reduction. These results suggest that in prospective chemoprevention trials, a significant risk reduction can be expected after only two years of aspirin use, in doses similar to those recommended for the prevention of cardiovascular disease, or nonaspirin NSAIDs [correction of nonaspirin. NSAIDs], in doses commonly prescribed for the management of musculoskeletal pain. The results also imply that any short-term reduction in the incidence of colorectal adenoma detected in a phase II trial would underestimate the chemopreventive effect of NSAIDs on the risk of adenocarcinoma.

Adenocarcinoma↗

PubMed1993

Is age a risk factor for surgery?

The question of age as a risk factor for surgery is complicated. There are many factors that have an impact on mortality rates in surgical care of the elderly. The most important of these are the physiologic changes with aging, underlying disease states, the type of procedures performed, and whether the procedure is performed as an emergency. Although there are many risks in performing surgery in elderly patients, there are many patients who do well and benefit from undergoing surgical procedures. Age alone should never be used as the criterion to deny surgery indicated in an elderly patient.

Age Factors↗

PubMed1990

Perioperative responsibilities of the physician/geriatrician.

The number of elderly patients undergoing surgery is increasing. A model that identifies sources of perioperative risk to the elderly patient is presented and discussed. We suggest that the perioperative responsibility of the physician/geriatrician lies in a self-conscious examination of these sources of risk in order to maximize the likelihood of a beneficial outcome.

Age Factors↗

PubMed1985

Cost-effectiveness of computerized tomography and magnetic resonance imaging in dementia.

The benefits and costs of routinely using computerized tomography (CT) to diagnose surgically treatable causes of dementia compared to a more selective strategy were assessed, using a decision-analytic model, for hypothetical cohorts at 60, 70, and 80 years of age. The model was also used to project what the impact would be if magnetic resonance imaging (MRI) were to replace CT, assuming that MRI is a perfect test. Given plausible assumptions, routine CT could be expected to detect between 1 425 and 14 930 additional surgically treatable cases at an extra cost of between $0 and $49 million per 100 000 persons scanned. Replacing CT with MRI might yield an additional 70 to 150 cases of surgically treatable dementia, at an additional cost of $20-$30 million. Given current treatment limitations in dementia, it appears that, as a clinical tool, MRI will have little immediate health impact on this problem.

Cost-Benefit Analysis↗

PubMed1981

Impaired growth hormone secretion in the adult population: relation to age and adiposity.

Growth hormone (GH) release was studied in adults of normal stature, ages 21-86 yr. The subjects were 85-115% of ideal body weight, between the 5th and 95th percentiles in height, and free of active or progressive disease. 9 to 12 individuals in each decade from thirds to ninth were evaluated. The following criteria of GH status were measured: serum GH concentration, analyzed by radioimmunoassay at half-hour intervals for 4 h after onset of sleep, and at 1-h intervals from 8 a.m. to 4 p.m. in 52 subjects; daily retention of N, P, and K in response to 0.168 U human (h)GH/kg body wt3/4/day in 18 subjects; and plasma somatomedin C (SmC) level before and during exogenous hGH treatment in 18 subjects. All 10 individuals, 20-29 yr old, released substantial amounts of endogenous GH during both day and night (average peak serum GH obtained during day and night was 7.3 and 20.3 ng/ml, respectively); average plasma SmC was 1.43 U/ml (95% tolerance limits, 0.64-2.22 U/ml). There was no significant effect of exogenous hGH on elemental balances or on plasma SmC. In contrast, 6 of 12 individuals 60-79 yr old showed the following evidences of impaired GH release; peak waking and sleeping serum GH less than 4 ng/ml; plasma SmC less than 0.38 U/ml; a significant retention in N, P, and K; and a significant rise in plasma SmC, in response to exogenous hGH. Plasma SmC, serum GH during sleep, serum GH during the day, retentions of N, P, and K in response to exogenous hGH, and rise in plasma SmC in response to hGH were all intercorrelated (P less than 0.05). Plasma SmC less than 0.38 U/ml corresponded to peak nocturnal serum GH less than 4 ng/ml. The prevalence of plasma SmC less than 0.38 U/ml increased progressively from age 20 to 90: third decade, 0%; fourth, 11%; fifth, 20%; sixth, 22%; seventh, 42%; eight, 55%; and ninth, 55%. Within each decade, plasma SmC was inversely related to adiposity.

Adult↗